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Editorial
The new coronavirus disease (COVID-16) caused by 
SARS-CoV-2 has had, and is still having, a significative im-
pact in the whole world population and the Dermatologists, 
their patients and their students are not an exception.
Due to the obligatory confinement many health resources 
had to shut down, Dermatologists had their jobs restricted, and 
the appointments of our patients were postponed, certainly with 
deleterious consequences for the patient and for the health re-
sources, namely in melanoma, where a 3-month delay can 
change a T1 into T2 melanoma with a consequent reduction 
in the estimated 5- or 10-year survival. In other situations, ap-
pointments were replaced by non-presential “consultations” by 
telephone, or other technological facilities like e-mail, What-
sApp, video-calls with some difficulties in communication and 
lesion visualization, but well-appreciated by some patients who 
saw the opportunity to resolve some questions without coming 
to the Hospital. Although these “appointments” are also highly 
time-consuming for the physician, certainly, some of the expe-
rience gained in this period will be kept in the future to monitor 
some patients with chronic diseases at a distance and prevent 
accumulation of patients in waiting-rooms. 
With this viral pandemic, dermatologists feared infection 
in their patients under treatment with immunosuppressive or 
biologic drugs. Most disease study groups, including the Por-
tuguese groups, issued recommendations on how to deal with 
these drugs during this pandemic. Happily, initial considera-
tions on the safety of therapies that interfere with IL-17, IL-23, 
IL-4 or anti-IgE, that were issued based only on the concep-
tual knowledge of the host antiviral immune response and 
the known mechanism of action of these drugs, have been 
confirmed through many recently published cases.1,2
Teaching of Dermatology, both pre and postgraduate tea-
ching, was completely changed with students receiving clas-
ses by several online platforms with the direct access to the 
patient’s words and his lesions completely denied and repla-
ced by photos where touch and three-dimensions of the le-
sions cannot be appreciated. Residents had their formation 
interrupted and some had to reinforce the medical teams in 
the COVID-19-dedicated wards. Certainly a unique and un-
forgettable experience! 
Dermatological manifestations were largely ignored (or 
absent) in China, where this pandemic began. But in Euro-
pean hospitals with a high number of COVID-19 patients, 
particularly in Italy and Spain, dermatologists also had to 
join teams caring for these patients and this revealed that 
Dermatology also has his place in caring COVID-19 pa-
tients. Recalcati from the Hospital of Lecco in Lombardy first 
reported cutaneous lesions in about 20% of COVID-19 pa-
tients.3 After him, multiple reports have called the attention 
to acral syndromes with chilblain-like or erythema multifor-
me-like lesions that occur mostly in young patients, some 
asymptomatic with negative naso-pharyngeal swabs and 
serology,4 cutaneous livedoid and vasculitic lesions usually 
associated with severe disease, lesions occurring late in the 
course of disease (exanthema) others as its presenting ma-
nifestation (acute urticaria),5 others possibly representing 
drug-induced maculopapular exanthema or severe adver-
se drug reactions (DRESS) whereas others suggest reactiva-
tion of other virus during the SARS-CoV-2 induced cytokine 
storm (pityriasis-rosea-like lesions or herpes zoster). There 
are two recent classifications of cutaneous lesions into 5 or 
6 subtypes, respectively by Galván-Casas et al, based on 
375 Spanish cases,6 and more recently by Marzano et al 
from Italy7: pseudo-chilblain lesions, urticarial lesions, ma-
culopapular exanthema, exanthema with vesicles, livedoid 
pattern and purpuric/necrotic/vasculitic lesions. Moreover, 
using histopathology, immunohistochemistry and other te-
chniques, dermatologists contributed to the understanding 
of cutaneous lesions: some are specific viral lesions, as both 
viral proteins and the receptors used for viral entry into the 
cells are expressed in the skin,8 whereas others are probably 
the expression of the exaggerated immune response to the 
virus.9 
Dermatology has also given another important contri-
bution in this pandemic with the prevention, diagnosis and 
treatment of irritant or allergic contact dermatitis or pressure 
ulcers in healthcare personnel wearing heavy personal pro-
tective equipment for many hours or of hand eczema in sus-
ceptible individuals who exaggerate hand cleaning and use 
of hydroalcoholic solutions.10  
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Editorial
Reflecting the importance of COVID-19 on Dermatolo-
gy there is an increasing number of publications on derma-
tological manifestations of SARS-CoV-2 infection and on its 
impact on dermatology (608 entries on PubMed for “COVID-
19” and “Dermatology” until June 14) although for the mo-
ment nothing appears in the Journal of SPDV. This is not due 
to the lack of Portuguese cases that have already been publi-
shed11 or are trying to be published elsewhere. It was there-
fore my commitment to call the attention to the importance 
of Dermatology in this pandemic and sincerely hope there 
is some national experience that may have a place in our 
journal.
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